Qinotto — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Qinotto is an early-stage, private biotech tackling one of the most significant challenges in neuroscience: delivering large-molecule drugs like antibodies, enzymes, and proteins to the brain. Its core asset is the QinoTrans platform, a discovery engine designed to identify new targets on the blood-brain barrier and develop engineered antibody vehicles that bind them to ferry therapeutic payloads into the CNS. The company is pre-clinical and pre-revenue, aiming to build a pipeline of first-in-class delivery vehicles that could become the foundation for best-in-class CNS therapeutics. Based in San Francisco, Qinotto operates in a high-potential but technically challenging field with significant unmet medical need.

Central Nervous System

Technology Platform

QinoTrans, a proprietary discovery platform that identifies novel blood-brain barrier (BBB) targets and engineers antibody-based vehicles to leverage endogenous pathways for delivering large molecule therapeutics to the brain.

Opportunities

The successful development of Qinotto's platform could unlock the vast market for biologic treatments in CNS disorders, including neurodegenerative diseases, brain cancers, and rare genetic disorders, which are currently untreatable due to delivery challenges.

The company also has significant potential as a partner for larger pharmaceutical companies seeking to enhance their CNS portfolios with effective delivery technology.

Risk Factors

The company faces high technical risk in validating its novel BBB targets and transport vehicles, as the biology is complex and preclinical success may not translate to humans.

As a pre-revenue, preclinical startup, it is also heavily dependent on venture funding and faces significant competition from other companies tackling the same fundamental problem.

Competitive Landscape

Qinotto operates in a competitive and active field of BBB drug delivery, competing with both public companies like Denali Therapeutics (with its Transport Vehicle platform) and numerous private biotechs and academic initiatives. Differentiation will depend on the novelty, efficiency, and safety profile of its discovered targets and engineered vehicles compared to existing approaches.

More companies in Drug Delivery & Formulation →More companies in United States →